Lifecore Biomedical, Inc. (NASDAQ:LFCR) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Analysts have a consensus rating of "Hold" on Lifecore from five brokerages (1 sell, 2 hold, 2 buy) with an average 12‑month price target of $6.00.
• In the most recent quarter Lifecore reported ($0.16) EPS, missing the consensus of ($0.11) while posting revenue of $35.75M (slightly above estimates) and showing a negative ROE and net margin.
• 83.36% of the stock is held by hedge funds and other institutional investors, with several firms (e.g., MIRAE, Price T. Rowe, AQR) recently increasing their positions.

Lifecore Biomedical, Inc. (NASDAQ:LFCR - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $6.00.

Several equities research analysts have recently issued reports on LFCR shares. Weiss Ratings reissued a "sell (d)" rating on shares of Lifecore Biomedical in a research note on Tuesday, April 21st. Barrington Research increased their target price on shares of Lifecore Biomedical from $5.50 to $6.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 29th.

Institutional Investors Weigh In On Lifecore Biomedical

Several hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Lifecore Biomedical by 14.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company's stock worth $104,000 after acquiring an additional 1,886 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Lifecore Biomedical by 92.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company's stock worth $43,000 after purchasing an additional 2,786 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Lifecore Biomedical by 20.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,646 shares of the company's stock worth $137,000 after purchasing an additional 2,826 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Lifecore Biomedical by 28.4% during the 4th quarter. AQR Capital Management LLC now owns 16,171 shares of the company's stock worth $132,000 after purchasing an additional 3,574 shares during the last quarter. Finally, Quarry LP acquired a new position in shares of Lifecore Biomedical during the 3rd quarter worth about $28,000. 83.36% of the stock is owned by hedge funds and other institutional investors.

Lifecore Biomedical Stock Up 0.6%

LFCR stock opened at $5.16 on Wednesday. The company's 50-day simple moving average is $5.29 and its 200-day simple moving average is $6.83. Lifecore Biomedical has a 52-week low of $3.63 and a 52-week high of $8.98. The firm has a market cap of $193.40 million, a P/E ratio of -5.27 and a beta of 1.08.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last posted its earnings results on Monday, March 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05). Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of 23.08%.The firm had revenue of $35.75 million for the quarter, compared to analysts' expectations of $35.31 million. On average, analysts anticipate that Lifecore Biomedical will post -0.88 earnings per share for the current fiscal year.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.